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This is an open access article distributed under the terms of the Creative Commons 
Attribution License 4.0 (CC BY) , which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
 
Abstract 
 
Chronic pain remains a prevalent and disabling problem for people living with the human 
immunodeficiency virus (HIV) in the current antiretroviral (ART) treatment era. Psychosocial 
treatments may have promise for managing the impact of this pain. However, research is 
needed to identify psychosocial processes to target through such treatments. The current 
systematic review and meta-analysis examined the evidence for psychosocial factors 
associated with pain, disability, and quality of life in people living with HIV and persistent 
pain. Observational and experimental studies reporting on the association between one or 
more psychosocial factor and one or more pain-related variable in an adult sample of 
people living with HIV and pain were eligible. Two reviewers independently conducted 
eligibility screening, data extraction, and quality assessment. Forty-six studies were included 
in the review and 37 of these provided data for meta-analyses (12493 participants). ‘Some’ 
or ‘moderate’ evidence supported an association between pain outcomes in people with 
HIV and the following psychosocial factors: depression, psychological distress, post-
traumatic stress, drug abuse, sleep disturbance, reduced ART adherence, healthcare use, 
missed HIV clinic visits, unemployment, and protective psychological factors. Surprisingly 
few studies examined protective psychological factors or social processes, such as stigma. 
There were few high quality studies. These findings can inform future research and 
psychosocial treatment development in this area. Greater theoretical and empirical focus is 
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needed to examine the role of protective factors and social processes on pain outcomes in 
this context. The review protocol was registered with PROSPERO (CRD42016036329). 
 
Key Words: HIV, pain, systematic review, psychosocial factors 
 
 
Introduction   
The human immunodeficiency virus (HIV) remains a significant global health concern 
with 36.7 million people living with HIV worldwide [130]. The availability of combined 
antiretroviral therapies (cART) has drastically improved life expectancy [9,93,120]. In well-
resourced countries, and increasingly in less well-resourced regions, the shift in HIV from a 
terminal illness to a chronic condition has led to a focus on disease and symptom 
management [59].  
Chronic pain is a common symptom in people with HIV. Data from one systematic 
review indicate that 54 to 83% of people with HIV may experience clinically-meaningful 
persistent pain, and these estimates appear stable from the pre- to current cART era [80]. 
Neuropathic pain is a frequent complication of HIV and/or antiretroviral therapy. 
Approximately 42 to 66% of people with HIV have peripheral sensory neuropathy (HIV-SN), 
and around 54-78% of these experience neuropathic pain [84,88,129]. Importantly, pain in 
people with HIV is associated with increased disability and reduced quality of life [27].   
There are few pharmacological options for managing chronic HIV-related pain. A 
systematic review of 19 randomized controlled trials (RCTs) of pharmacotherapy for painful 
HIV-SN found efficacy only for topical capsaicin, smoked cannabis, and subcutaneous nerve 
growth factor [85]. However, nerve growth factor is not clinically available, capsaicin is not 
feasible in lower-resourced settings, and a subsequent review of cannabis showed no effect 
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on neuropathic pain and concerns about long-term side-effects [32]. Additional negative 
RCTs of pregabalin, capsaicin, and amitriptyline have been published [17,24,103].  
In the wider literature, psychological approaches are common in chronic pain 
management [34]. Psychological treatments, including cognitive-behavioural therapy (CBT), 
are associated with improved functioning and mood for chronic pain that is primarily 
musculoskeletal [124]. However, research on psychological treatments for pain in HIV is less 
well developed. Only two RCTs have examined CBT for people with HIV and chronic pain, 
but interpretation of these trials is hampered by small samples [118] and high drop-out 
rates [29]. An observational study of CBT for HIV-related pain showed similarly poor 
treatment completion [21,113]. There is a clear need for improving psychological 
treatments for people with HIV-related pain.  
Improving psychological approaches for chronic pain in HIV will require 
consideration of the psychosocial complexities associated with HIV. For example, stigma, 
mental health problems, and substance abuse may influence pain and treatment 
engagement in people with HIV [36,69,71,111,123,132]. However, research has not 
systematically examined psychosocial factors associated with pain in this context. The 
systematic review by Parker et al. (2014) which estimated the prevalence of pain in HIV 
described five studies reporting psychosocial factors. However, that review did not 
specifically include assessment of psychosocial factors in the eligibility criteria. Furthermore, 
33 potentially eligible studies were excluded due to low quality ratings [80], which limits our 
understanding of the range of psychosocial factors examined in this context. Therefore, we 
conducted a systematic review and meta-analyses to examine the associations between 
psychosocial factors and persistent pain in HIV. As the aims of the review were exploratory, 
we did not formulate specific hypotheses about the associations between these variables. 
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Methods 
The review protocol was registered with PROSPERO 
(http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42016036329).  
Inclusion and Exclusion Criteria 
Inclusion:  
1) People with HIV > 18 years old. 
2) The original protocol specified the study must have a ‘(sub)sample with average pain 
duration of >3 months’. After piloting this criterion, a large number of studies did not define 
or report pain duration. We contacted authors to enquire about pain chronicity; however, 
these data were generally not available. Given the potentially high prevalence of chronic 
pain in HIV [80], we decided to include studies with (sub)samples of ambiguous pain 
duration, provided that “pain” versus “no pain” subgroup analyses were reported in studies 
for which chronic pain was not an eligibility criterion or which did not report pain duration.  
3) Data on presence of pain, pain intensity, functioning, and/or quality of life.  
4) Data on one or more psychosocial variable, representing any potentially modifiable 
cognitive, affective, behavioural, or interpersonal process. Adherence to antiretroviral 
therapy and healthcare use variables represent modifiable behaviour patterns. Therefore, 
we considered these as psychosocial variables eligible for this review. 
5) Observational (cross-sectional, case-control, or prospective) or experimental studies 
(RCTs) reporting between- or within-groups associations between pain and psychosocial 
variables in a (sub)sample with pain.  
7) Any language, from any region, from 1981 onwards (the date that HIV was identified in 
the literature). 
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8) Studies (published and unpublished) with an available full-text. Where only abstracts or 
trial registration summaries were available, the authors provided unpublished data for the 
review. Unpublished studies are commonly included in systematic reviews given recognition 
of overestimation of effects in published research [62]. Additionally, studies conducted in 
lower-resourced countries where HIV is particularly prevalent may not always proceed 
through to publication. Therefore, the inclusion of unpublished studies and dissertations 
may help overcome this disparity and allows us to consider potential contextual differences. 
Exclusion:  
1) Studies only measuring associations between unchangeable demographic factors (e.g., 
age, ethnicity) and pain. While piloting the eligibility criteria, we found a number of studies 
reporting history of injecting drug use (IDU) as participants’ HIV risk factor. Given lack of 
further information about substance abuse history or current abuse, we excluded studies 
for which IDU history was the only psychosocial factor. Likewise, we excluded studies 
reporting only average units of alcohol consumed, rather than alcohol abuse.  
2) Qualitative studies. 
Search Strategy: 
We searched the following databases during March 2016: Medline, EMBASE, 
CINAHL, PsycINFO, Cochrane, and Web of Science. We also searched ISRCTN, 
clinicaltrials.gov, and EU Clinical Trials Register. Reference lists of eligible studies were 
searched and key authors were contacted. We re-ran the search in August 2017. The search 
included terms for the target population (HIV or AIDS), outcome (chronic pain), and 
exposure measurement (psychosocial factors). Relevant search terms were identified from 
previous reviews on pain in HIV [80,124], psychosocial factors in HIV [99], and psychosocial 
factors in chronic pain [40] (Appendix A). 
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Data extraction  
Two reviewers (WS and CA) independently screened titles/abstracts and full-texts for 
eligibility. The following data were extracted from eligible studies: year; design; country; 
sample size; demographics (i.e., age, sex, and race/ethnicity); clinical factors (i.e., HIV 
duration, use of ART, CD4+ count and viral load, pain duration and type); assessment of pain 
and psychosocial variables; and, statistical analyses. In cases where both cross-sectional and 
prospective data reported the same (or an overlapping) cohort and variables, the 
prospective analyses were extracted. Data were extracted from all studies by WS, and 
independently by CA and KK who each extracted data from approximately half of the 
studies. Disagreements regarding eligibility and data extraction were discussed to reach 
consensus and, where discrepancies remained, WS discussed these with the wider team. 
The reviewers were not blinded to the authorship of the studies reviewed.  
Quality Assessment 
We assessed the methodological quality of studies using an adapted version of 
quality assessment tools used in previous systematic reviews of observational studies 
relevant to pain and HIV [3,40,80]. The quality assessment tool contained items assessing: 
study purpose, recruitment, response rates, sample description, assessment measurements, 
data analysis, and confounding/matching (Appendix B). Additional items assessed features 
specific to prospective designs. Thus, quality scores differed for cross-sectional and 
prospective studies. In some cases, the overall study design did not correspond to the 
nature of the data extracted for the purpose of this review. Additionally, in some cohorts a 
cross-sectional design was used to examine one psychosocial variable, while a prospective 
design was used to examine another variable using the same sample. In all cases, the quality 
assessment was applied to the design used for the nature of the data extracted for a given 
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psychosocial variable. Quality assessment items were rated as ‘positive’ (1), ‘negative’ (0), or 
‘unclear’ (?), and total scores were computed and classified as low (<50%), medium (50–
80%), and high (>80%) [3,40]. WS completed quality assessment ratings for all studies, while 
CA and KK each independently completed the quality assessment for approximately half of 
the studies. The strength of evidence was assessed according to the levels outlined by 
Ariens et al. in a systematic review of observational studies of psychosocial risk factors for 
neck pain [3]: 1) Strong: Consistent results in multiple high quality prospective and/or case-
control studies; 2) Moderate: Consistent results in multiple prospective and/or case-control 
studies; 3) Some Evidence: Findings in one prospective or case-control study, or consistent 
findings in multiple cross-sectional studies with at least one high quality study; and 4) 
Inconclusive: Inconsistent findings in multiple studies or consistent findings in multiple low 
quality cross-sectional studies [3]. 
Data Synthesis 
Meta-analyses were conducted using Stata 15.0 where there were at least two 
studies [43] with the same design and effect estimate of the association between the same 
pain (e.g., intensity) and psychosocial variables (e.g., depression). We took a broad approach 
to the meta-analyses [37,45], and grouped psychosocial variables on the basis that they 
reflected conceptually similar underlying constructs with overlapping measurement 
content. All analyses were conducted using random effects given likely heterogeneity [43]. 
Between-study heterogeneity (I
2
 statistic) was interpreted as low (<25%), medium (25-50%), 
and high (>50%) [124]. For between-groups comparisons of continuous data, means, 
standard deviations, and sample sizes were extracted to compute the pooled standardized 
mean difference (SMD). For between-groups comparisons of dichotomous data, events data 
and sample sizes were extracted. Where events data were not reported, odds or hazard 
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ratios, 95 percent confidence intervals (95% CIs), and sample sizes were extracted. To 
aggregate studies reporting a mixture of odds ratios and events data, odds ratios were first 
computed from studies reporting events data and then pooled with odds ratios reported in 
other studies. Odds ratios and hazard ratios were analysed separately. Where applicable, 
correlation coefficients (Pearson’s r) were extracted with sample sizes. We transformed r to 
Fisher’s z and computed 95%CIs of z to compute the pooled estimate [18,100].  
Data extracted were from bivariate analyses. Multivariate data (e.g., adjusted odds 
ratios) were only extracted where bivariate data were not available. We focused on 
bivariate analyses, as many studies did not report multivariate analyses. Moreover, studies 
that reported multivariate models varied substantially with respect to control variables 
included, and inconsistently used psychosocial variables as independent or dependent 
variables. Taken together, these differences limit meaningful interpretation of multivariate 
analyses across studies. 
Several studies presented data on more than two pain/no pain groups, often with 
idiosyncratic group definitions, which limited our ability to compare studies. Where studies 
reported three or more groups, we collapsed these into two to represent groups with and 
without pain (e.g., frequent/moderate/severe versus infrequent/mild/none), and computed 
effects between these. This approach facilitated more direct comparison across studies and 
thus enabled us to include a larger number of studies in the analyses. For studies comparing 
participants on the presence of neuropathy, we prioritised extracting data from these 
comparisons in the following order depending on the data reported: 1) painful versus non-
painful neuropathy; 2) painful neuropathy versus no neuropathy; and 3) neuropathy versus 
no neuropathy. Where there was more than one measure of the same variable, we 
extracted data for the measure with the widest usage or the longer measure to increase 
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reliability [124]. Our protocol specified that funnel plots would be inspected to assess for 
publication bias. However, due to the relatively small number of studies in each meta-
analysis and the likelihood of high heterogeneity, inspection of funnels plots was not 
appropriate [109] and, therefore, was not undertaken.  
We conducted sensitivity analyses to examine the influence of the following study 
and patient characteristics on the findings: certainty of pain chronicity, pain type, immune 
functioning and viral suppression, ART treatment era, and healthcare system. With the 
exception of the pain chronicity analysis, these sensitivity analyses were pre-specified. Given 
the large number of potential analyses, we restricted sensitivity analyses to the between-
groups SMDs for depression, as this was the analysis with the largest number of studies.  
 
Results 
 Forty-six studies were included in the review (13480 participants) and 37 of these 
provided data for meta-analyses (12493 participants). Most (83%) were conducted in the 
United States (US), with four studies from South Africa [79,88,121,122], and one each from 
the United Kingdom (UK) [84], Thailand [89], Uganda [95], and Russia [114]. Participants 
were primarily recruited from HIV clinics, or using multifaceted strategies that also included 
recruitment from substance abuse clinics and community outreach. One study recruited 
exclusively from a methadone clinic [8], while two others recruited in high poverty areas 
[39,110]. The samples were comprised predominantly of men in 41 studies, with the 
proportion of men in these studies ranging from 51% [50] to 100% [28,104]. Five studies 
(four from South Africa, one from the US) recruited women exclusively [79,92], or 
predominantly (proportion of women ranging from 72-88%) [88,121,122]. The mean age 
ranged from 30.1 (SD=5.2) [114,115] to 51.0 (SD=9.3) years [119]. HIV duration was not 
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consistently reported; however, of the studies providing data, duration ranged from 2.09 
(SD=1.22) [102] to 16.95 years (SD=8.70) [119]. Eighteen studies (39%) reported on mixed 
HIV/AIDS samples (reported proportion with AIDS ranged from 10-74%). Four studies 
included only participants with AIDS, one study excluded patients with AIDS, while 23 
studies did not clearly report the proportion (if any) with AIDS. Supplemental Table 1 shows 
further demographic characteristics of the study samples (available at 
http://links.lww.com/PAIN/A643). 
 Table 1 provides a summary of study designs, quality, and evidence level for each 
psychosocial factor. The studies showed substantial variability in the measurement of pain 
and psychosocial variables. Most studies (63%) were medium quality. Fifteen studies were 
low quality, and only two were high quality [79,84]. The most common limitations included 
unclear reporting of response rates, no a priori sample size justification, and poor reporting 
of HIV and pain characteristics. There is no single agreed upon strategy to best address low 
quality studies within meta-analyses, an issue which is compounded by the arbitrary nature 
of study quality scoring and cut-off points [43]. This can be dealt with by only including high 
quality studies, performing sensitivity analyses, or including all studies irrespective of quality 
and discussing risk of bias [43]. Given that only 2 of 46 studies were rated as high quality, a 
meta-analysis of these cannot be regarded as reflecting most of the studies. Sensitivity 
analyses would likewise not be meaningful. Including all studies is thus the most justifiable 
approach for the current data. Although we have chosen to focus on data from bivariate 
analyses for reasons outlined in the Methods, studies that reported a multivariate model of 
the association between psychosocial and pain variables are shown in bold in Table 1 for 
ease of reference. 
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Depression 
Depression was the most frequently assessed psychological variable, investigated in 
29 studies. Two prospective studies reported hazard ratios for baseline depression 
predicting time to onset of symptomatic neuropathy. The pooled hazard ratio was 
significant and indicated that baseline depression was more severe in participants who 
developed symptomatic neuropathy at follow-up than those who did not: HR=1.04 (95% CI 
1.02-1.07), z=3.23, p=0.001 (Supplemental Figure 1, available at 
http://links.lww.com/PAIN/A643). Heterogeneity was 0.0%. Two further prospective studies 
reported odds ratios. The pooled odds ratio was significant and indicted that higher baseline 
depression symptoms were associated with greater likelihood of follow-up pain: OR=2.26 
(95% CI 1.47-3.47), z=3.72, p<0.001 (Supplemental Figure 2, available at 
http://links.lww.com/PAIN/A643). Heterogeneity was medium (40.1%). Nine cross-sectional 
studies provided events data or odds ratios. The pooled odds ratio was significant such that 
depression was more likely in participants with versus without pain: OR=2.65 (95% CI 1.62-
4.34), z=3.90, p<0.001 (Figure 2). Heterogeneity was high (83.0%). Twelve cross-sectional 
studies provided data to compute SMDs (Figure 3). The overall effect was significant and 
showed moderately greater depression in participants with versus without pain: SMD=0.68 
(95%CI 0.42-0.93), z = 5.22, p<0.001. Heterogeneity was high (I
2
=89.2%). Another cross-
sectional study which reported the median and interquartile range found no difference in 
depression between groups with (n=125) and without pain (n=72) [88]. 
Six cross-sectional studies reported correlation coefficients between depression and 
pain severity. The pooled correlation was small, but significant: Fisher’s z=0.26 (95% CI 0.18-
0.33), z=6.77, p<0.001. Heterogeneity was 0.0%. One additional study found a non-
significant correlation, although the coefficient was not reported [27]. Four cross-sectional 
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studies reported correlations between depression and pain interference/disability. The 
pooled correlation was moderate: Fisher’s z=0.48 (95% CI 0.41-0.56), z=12.48, p<0.001. 
Heterogeneity was 0.0%. Three cross-sectional studies reported correlations between 
depression and quality of life. The pooled correlation was large and significant: Fisher’s z=-
0.52 (95% CI -0.75 to -0.30), z=4.51, p<0.001. Heterogeneity was high at 73.3% (all 
correlation analyses, Supplemental Figure 8, available at http://links.lww.com/PAIN/A643). 
One final cross-sectional study (n=120) reported a moderate correlation between pain 
presence and depression [55].  
 
Depression Sensitivity Analyses  
We conducted sensitivity analyses on the SMDs for depression between pain and no 
pain groups (Supplemental Figures 3-7, available at http://links.lww.com/PAIN/A643). We 
excluded data from the Kirkland study here, as the SMD from this study was substantial and 
appeared to be driving heterogeneity in the primary meta-analysis. Excluding the Kirkland 
data reduced heterogeneity from I
2
=89.2% to 52.2%. Thus, eleven studies were included in 
sensitivity analyses. 
The pooled SMD for depression was medium for studies with certain (0.61, 95% CI 
0.11-1.12, z=2.39, p=0.02; I
2
=75.1%) and uncertain pain chronicity (0.53, 95%CI 0.41-0.64, 
z=9.04, p<0.001; I
2
=34.5%). In the analysis by pain type, the pooled SMD for depression was 
moderate in studies with mixed pain types (0.75, 95%CI 0.58-0.92, z=8.51, p<0.001; 
I
2
=31.7%) and for which pain type was not reported (0.52, 95%CI 0.39-0.65; z=7.91, p<0.001; 
I
2
=0.0%). In contrast, studies with neuropathic pain (0.31, 95%CI 0.11-0.52; z=2.96, p=0.003; 
I
2
=0.0%) or headache (0.38, 95%CI 0.06-0.70, z=2.34, p=0.02) showed small but significant 
differences between groups on depression. 
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The pooled SMD for depression was moderate for studies in which participants had 
less than adequate immune functioning and viral suppression (0.56, 95%CI 0.42-0.70, 
z=7.77, p<0.001; I
2
=0.0%) and for studies in which these indicators were uncertain (0.53, 
95%CI 0.33-0.73, z=5.28, p<0.001; I
2
=69.1%). There were no studies with ‘adequate’ 
functioning on these indices in this analysis. Studies from the pre-cART (0.49, 95%CI 0.32-
0.66, z=5.75, p<0.001; I
2
=0.0%), cART (0.73, 95%CI 0.37-1.10, z=3.91, p<0.001), and current 
cART era (0.55, 95%CI 0.38-0.72, z=6.21, p<0.001; I
2
=62.5%) all had moderate or near 
moderate pooled SMDs. Lastly, pooled SMDs for depression were similar in studies from the 
US which has a mixed healthcare system (0.57, 95%CI 0.43-0.72, z=7.58, p<0.001; I
2
=55.7%) 
and one study from the UK, which has universal healthcare (0.68, 95%CI 0.09-1.28; z=2.25, 
p=0.03). The pooled SMD of two studies conducted in lower- and middle-income countries 
was smaller, but statistically significant (0.43, 95%CI 0.14-0.72, z=2.90, p=0.004; I
2
=54.2%). 
 
Psychological Distress  
Eighteen studies examined variables representing psychological distress, including 
anxiety-related constructs and the presence of ‘mental illness’, which generally described a 
combination of anxiety and depression. Five cross-sectional studies provided events data 
(Figure 4). The pooled odds ratio was significant and indicated that participants with pain 
were more likely to have psychological distress than those without pain: OR=2.56 (95% CI 
1.67-3.90), z=4.34, p<0.001. Heterogeneity was high (I
2
=68.3%). One prospective study 
(n=127) found that baseline mental illness did not predict presence of pain over follow-up 
[54]. Seven cross-sectional studies provided means and standard deviations (Figure 5). The 
pooled SMD showed a large and statistically significant difference between groups such that 
distress was worse in participants with versus without pain (SMD=0.85, 95% CI 0.35-
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1.35); z = 3.33, p = 0.001). Heterogeneity was very high (I
2
=95.4%). One further study which 
reported the median and interquartile range found no difference between groups [88].  
Four cross-sectional studies reported correlations between distress and pain severity 
(Supplemental Figure 9, available at http://links.lww.com/PAIN/A643). The pooled 
correlation was moderate: Fisher’s z=0.35 (95% CI 0.09-0.60), z=2.68, p=0.007. 
Heterogeneity was high (82.2%). Three cross-sectional studies reported correlations 
between distress and pain interference/disability. The pooled correlation was moderate: 
Fisher’s z=0.59 (95% CI 0.24-0.93), z=3.34, p=0.001. Heterogeneity was high (81.2%). One 
prospective study (n=45-62) found a non-significant correlation between change in distress 
and pain severity following cognitive-behavioural therapy, and a significant, moderate 
correlation between change in distress and pain interference [44,86]. Lastly, one cross-
sectional study reported a non-significant correlation between pain intensity and distress (r 
not reported), and a small negative correlation between distress and quality of life [88]. 
 
Post-Traumatic Stress  
Three studies investigated post-traumatic stress. These studies are reported 
separate from studies measuring psychological distress, given the specificity of post-
traumatic stress as a variable. Different study designs and analyses precluded meta-analysis. 
One prospective study (n=143) found that post-traumatic stress symptoms (PTSS) were 
associated with significantly higher pain severity and interference over time in a sample 
with HIV and persistent pain [107]. One high quality cross-sectional study found that 
participants with pain (n=170) had significantly higher PTSS than those without pain (n=59) 
[79]. Within the pain group in this study, there was a non-significant correlation between 
PTSSs and pain severity, and small but significant correlations between PTSSs and pain 
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interference (positive correlation) and quality of life (negative correlation) [79]. Post-
traumatic stress disorder did not differ between groups with (n=150) and without (n=128) 
neuropathy in another cross-sectional study [31].  
 
Drug Abuse 
Fourteen studies examined drug abuse. We prioritised extracting opioid abuse data 
when multiple drug abuse categories were reported given the relevance of opioid use in 
chronic pain. Two prospective studies reported odds ratios for pain predicting heroin use at 
the time of follow-up. The pooled odds ratio indicated that participants with pain at 
baseline were more likely at follow-up to be using heroin: OR=1.70 (95%CI 1.22-2.38), 
z=3.13, p=0.002 (Supplemental Figure 10, available at http://links.lww.com/PAIN/A643). 
Heterogeneity was low (I
2
= 14.0%). Conversely, another prospective study (n=493) reported 
that baseline opioid use disorder history predicted new onset of neuropathic pain, OR=2.87 
(1.31-6.28), p<0.01 [60]. One low quality prospective study (n=127) found that baseline drug 
abuse history did not predict the presence of pain at follow-up, 0.55 (0.25-1.21) [54]. These 
two studies could not be combined due to different coding of the dependent variable. 
Eight cross-sectional studies reported events data (Figure 6). The pooled odds ratio 
was significant such that participants with pain were more likely to have co-morbid drug 
abuse than those without pain: OR=1.59 (95%CI 1.12-2.26), z=2.58, p=0.01. Heterogeneity 
was high (I
2
=69.8%), mainly attributable to one study which found the opposite effect, such 
that participants with symptomatic distal sensory polyneuropathy (DSP) were less likely to 
have opioid use disorder than those with asymptomatic DSP [76]. One low quality cross-
sectional study (n=503) found that participants with ‘untreated’ pain had greater 
dependence symptoms than those with ‘treated’ pain or without pain [110]. Another low 
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quality cross-sectional study (n=73) found a small positive correlation between ‘aberrant 
drug behaviours’ and pain interference, but not quality of life [81].  
 
Alcohol Abuse  
Eleven studies investigated alcohol abuse. Two prospective studies reported odds 
ratios for baseline pain predicting subsequent alcohol abuse. The pooled odds ratio was not 
significant: OR=0.94 (95% CI 0.39-2.26), z=0.13, p=0.90 (Supplemental Figure 11, available at 
http://links.lww.com/PAIN/A643). Heterogeneity was high (84.1%). Two additional 
prospective studies examined baseline alcohol abuse as a predictor of developing 
pain/neuropathy but could not be combined due to different analyses. Both studies 
reported a non-significant association between these variables [60,77]. Seven cross-
sectional studies provided events data or odds ratios. The pooled odds ratio was not 
significant: OR=1.22 (95%CI 0.92 to 1.62), z=1.36, p=0.17 (Supplemental Figure 12, available 
at http://links.lww.com/PAIN/A643). Heterogeneity was medium (I
2
=39.0%).  
 
Sleep Disturbance  
 Three studies investigated sleep disturbance. Two cross-sectional studies reported 
means and standard deviations. The pooled effect was significant and showed moderately 
greater sleep problems in participants with versus without pain: SMD=0.66 (95% CI 0.45-
0.87), z=6.12, p<0.001. Heterogeneity was 0.0% (Supplemental Figure 13, available at 
http://links.lww.com/PAIN/A643). Another cross-sectional (n=45) study reported a 
significant correlation between pain severity and sleep disturbance, and a non-significant 
correlation between sleep and functioning [94].  
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ART Non-Adherence  
 Seven studies investigated the association between pain and suboptimal ART 
adherence. Data were analysed separately according to whether the adherence variable was 
coded in the direction of non-adherence or adherence. One prospective study (n=258) 
reported that severe pain at baseline predicted higher odds (OR=1.37, 95%CI 1.02 to 1.85) 
of follow-up ART non-adherence [46]. One cross-sectional study provided events data while 
another provided an odds ratio. The pooled odds ratio was significant and indicated that 
participants with pain were more likely to report non-adherence: OR=1.40 (95% CI 1.07 to 
1.82), z=2.50, p=0.01 (Supplemental Figure 14, available at 
http://links.lww.com/PAIN/A643). Heterogeneity was 0.00%. One cross-sectional study 
(n=42) found significant positive correlations between pain severity and adherence 
forgetfulness and fears [57].  
Two cross-sectional studies reported data for the association between pain and 
adherence (events data or odds ratio). The pooled odds ratio was less than one,  indicating 
the likelihood of adherence was lower in participants with pain, but this was not statistically 
significant: OR=0.32 (95% CI 0.08 to 1.32), z=1.57, p=0.12 (Supplemental Figure 15, available 
at http://links.lww.com/PAIN/A643). Heterogeneity was high (74.3%). Lastly, one low-
quality cross-sectional study (n=377) found that pain presence was not associated with 
adherence in a structural equation model [72].  
 
Healthcare Use  
 Six studies examined healthcare use. One prospective study (n=1521) found that 
baseline pain predicted significantly higher odds (OR=1.6, 95%CI 1.2-2.0) of urgent care 
visits [68]. Two cross-sectional studies reported events data. The pooled odds ratio was not 
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significant: OR=0.98 (95% CI 0.58-1.66, z=0.07, p=0.94 (Supplemental Figure 16, available at 
http://links.lww.com/PAIN/A643). Heterogeneity was 0.0%. Two further cross-sectional 
studies reported means and standard deviations. The pooled effect was small but 
significant, such that participants with pain had greater healthcare use than those without 
pain: SMD=0.36 (95% CI 0.21-0.51), z=4.66, p<0.001). Heterogeneity was 0.0% 
(Supplemental Figure 17, available at http://links.lww.com/PAIN/A643). One further cross-
sectional study (n=1120) found that participants with pain and daily opioid use had more 
clinic visits than those with pain without daily opioid use and those without pain (standard 
deviation not reported) [53].  
 
Missed HIV Clinic Visits  
Two prospective studies reported odds ratios for baseline presence of pain predicting 
missed HIV clinic visits over one year follow-up. The pooled odds ratio was significant, such 
that those with pain at baseline had higher odds of a missed HIV clinic visit: OR=1.42 (95% CI 
1.13-1.79), z=2.98, p=0.003 (Supplemental Figure 18, available at 
http://links.lww.com/PAIN/A643). Heterogeneity was 0.0%.  
 
Unemployment  
Seven cross-sectional studies provided events data or odds ratios for the association 
between unemployment and pain. The pooled odds ratio was significant, and indicated that 
participants with pain had higher odds of being unemployed than those without pain: 
OR=2.09 (95% CI 1.59-2.76), z=5.25, p<0.001 (Supplemental Figure 19, available at 
http://links.lww.com/PAIN/A643). Heterogeneity was moderate (48.6%). One further cross-
sectional study (n=229) that did not have data available for meta-analysis likewise found 
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that participants with pain were significantly more likely to be unemployed than those 
without pain [79]. 
 
Protective Factors 
Five studies examined protective psychological factors. One prospective study (n=62) 
found significant small and medium correlations between change in self-reported pain 
acceptance during CBT and post-treatment pain severity and interference, respectively [86]. 
One cross-sectional case-control study observed lower resilience in participants with (n=99) 
versus without pain (n=98; medium effect); however, this study found non-significant 
correlations between resilience and pain severity and interference in the pain group [121].  
One high quality cross-sectional study found that participants with pain (n=170) 
reported lower disease management self-efficacy than did those without pain (n=59) (small 
effect) [79]. Within the pain group in this study, there were non-significant correlations 
between self-efficacy and pain severity and interference, and a small positive correlation 
between self-efficacy and quality of life [79]. One low quality cross-sectional study found 
that those with greater adherence self-efficacy were less likely to report pain (n=70) [8]. 
Lastly, one low quality cross-sectional study found lower mean self-reported optimism in 
participants with (n=50) versus without pain (n=46) (small effect) [101].  
 
Social Factors 
Four studies investigated social factors. The BEACON study (n=377) explored social 
processes across three papers, two of which describe prospective data (medium quality) 
while the third reported cross-sectional data (low quality). Baseline chronic pain predicted 
“negative social support” (i.e., overly intrusive or insensitive responses from others and a 
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lack of support) at 12 months, controlling for baseline social support [73]. Another 
prospective analysis showed that no chronic pain at baseline predicted greater support 
reciprocity at follow-up [74]. Chronic pain was associated with significantly poorer ratings of 
patient-provider engagement in cross-sectional analyses [72].  
Two studies examined self-reported stigma, but could not be combined. One 
medium quality cross-sectional study (n=50) found a moderate positive correlation between 
stigma and pain severity [122]. One low quality cross-sectional study (n=201) found that 
participants with ‘Pain Disorder’ reported higher stigma scores than those without ‘Pain 
Disorder’[98]. One medium quality cross-sectional study found no difference in mean 
number or quality of self-reported social supports between participants with (n=274) and 
without pain (n=164) [91].  
 
Discussion 
 This review including over 13000 participants found ‘some’ or ‘moderate’ evidence 
supporting an association between pain outcomes and depression, psychological distress, 
post-traumatic stress, drug abuse, sleep disturbance, healthcare use, missed HIV clinic visits, 
ART adherence, unemployment, and protective psychological factors in people with HIV. 
Surprisingly few studies have examined protective psychological factors or social processes. 
There is a lack of high quality research on psychosocial factors related to chronic pain in 
people with HIV. These findings can inform future research and treatment development in 
this area. 
The association between depression and poorer self-reported pain outcomes in HIV 
is consistent with the wider pain literature [4,64]. Data from prospective studies suggest 
depression is a risk factor for pain. However, caution is warranted in this interpretation 
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given the observational nature of studies. There is likely a bi-directional relationship, with 
shared neurobiological pathways, cognitive appraisals, and behavioural disengagement 
underpinning this association [4,7,14]. Evidence supporting the association between pain 
and sleep disturbance is consistent with the wider literature that reports reciprocal 
associations between pain, sleep, and depression [106].  
There was substantial variability in the assessment of ‘psychological distress’, which 
may have contributed to the statistical heterogeneity observed. Although different 
measures were used to assess variables such as pain catastrophizing, pain-related fear, 
stress, and general anxiety, these measures overlap conceptually and in item content. The 
consistency of results within the psychological distress category suggests the findings are 
robust across different assessment methods. Several studies assessed ‘mental illness’ based 
on a range of diagnoses in participants’ medical file without clear diagnostic criteria. Studies 
exploring mental health diagnoses should use valid and reliable criteria and, ideally, semi-
structured clinician-administered interviews as the gold standard (e.g., [128]).  In light of 
high rates of PTSD in HIV [99], further research is particularly needed to understand the role 
of PTSD in pain in this context. Alternately, rather than focusing on specific mental health 
diagnoses, research investigating psychosocial processes that explain the impact of a range 
of psychological difficulties may prove useful moving forward [42]. 
Few studies investigated fear-avoidance model (FAM) variables, such as pain 
catastrophizing and pain-related fear, which have dominated the musculoskeletal pain 
literature. Fear of movement is strongly associated with musculoskeletal pain disability [20]. 
However, neuropathic pain is often spontaneous and not clearly provoked by movement, 
although it may inhibit movement. Therefore, research is needed to determine the 
relevance of FAM constructs in neuropathic pain which is common in HIV [19]. 
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A bi-directional association between drug abuse and pain in HIV is suggested by 
prospective data showing opioid abuse as both predictor [60] and outcome [114] of pain. In 
a population where there are concerns about analgesic prescribing [58], poorly managed 
pain may contribute to increased abuse of non-prescribed opioids, which may be 
exacerbated by depression [114]. Alternately, prolonged opioid abuse may disrupt 
descending pain inhibition, exacerbating pain [49]. Differing definitions of drug and alcohol 
abuse across studies may account for variability in effects. Future research on substance 
abuse in this context should use validated assessments, either screening tools or diagnostic 
interviews that capture key features of abuse, such as continued use despite harm 
[1,41,128].  
 Adherence to ART and retention in care are psychosocial factors unique to the HIV 
context, and are of vital importance given their associations with mortality, morbidity, and 
drug resistance [112]. The finding that pain was associated with reduced ART adherence and 
missed HIV clinic visits highlights the necessity of adequate pain management in HIV. 
Understanding the links between pain, ART adherence, and retention in care likely requires 
consideration of other psychosocial factors, such as substance abuse and depression, which 
may mediate or moderate this association [68,92].  
Findings that pain was associated with greater unemployment and healthcare use 
highlight the individual, societal, and economic costs of pain in HIV. This is consistent with 
the broader literature, although healthcare use is typically under-assessed in trials of 
psychotherapy for chronic pain [87]. Studies assessing healthcare use were restricted to the 
US, while the unemployment-pain link was consistent in studies from the US, Russia, and 
South Africa. The association between pain and healthcare use differed across studies on 
the basis of the type of healthcare assessed. Assessment of the most frequently accessed 
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services (e.g., GP visits), rather than relatively infrequent events (e.g., hospitalisations) may 
increase the interpretability of future healthcare data.   
 Surprisingly, only five studies assessed protective psychological factors. The lack of 
studies on protective factors mirrors historical trends in the general pain literature, although 
there has been greater focus on protective factors more recently. The focus on  
‘maladaptive’ responses to pain is problematic, as such responses can be understood as a 
function of their short-term utility [126]. Moreover, abnormal conceptualizations often fail 
to specify pathways through which recovery and successful functioning occur when pain is 
present. The psychological flexibility model, within which pain acceptance has been 
conceptualised, might prove useful for future research [63]. 
  A recent proposal for updating the definition of pain highlights the central role of 
social factors [127]. However, our review identified only four studies exploring interpersonal 
variables. The lack of research on stigma in relation to pain is particularly surprising as 
managing stigma is key to the success of the HIV/AIDS response [108]. Stigma has recently 
been highlighted as important for the well-being of patients with chronic pain in general 
[23,125]. Future research is needed to determine the function of stigma in chronic pain in 
people with and without HIV.  
The study samples included in our review varied widely in terms of the proportion of 
men and women, participant age, ethnicity, and duration and severity of HIV. Our sensitivity 
analyses support the potential applicability of findings across pain types, ART treatment 
eras, and healthcare systems. Due to poor reporting of viral loads and CD4+ counts, our 
analysis stratifying by these indicators is difficult to interpret. Caution is also warranted 
regarding the cross-cultural applicability of the findings, as most studies were from the US. 
One South African study with a predominantly female sample found patients with and 
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without pain did not differ on depression or anxiety, likely due to high scores across the 
sample [88]. Socioeconomic factors, such as poverty and gender, may thus alter the 
relationships between pain, functioning, and mental health [88,121]. Care is needed in 
applying Western psychological concepts in non-Western cultures [51,82,83]. Research must 
also determine unique cultural features that influence the experience and expression of 
pain in HIV. 
 A guiding theoretical model is needed to integrate psychosocial processes relevant 
to pain and HIV. Such a model should make specific predictions about the relative 
contributions of cognitive, affective, behavioural, and sociocultural processes in relation to 
specific pain outcomes. This review identified a number of closely related psychosocial 
constructs. Therefore, a theoretical model may benefit from identifying a key set of non-
overlapping variables [63]. This may draw on prominent models within the field of pain, 
such as the fear-avoidance [19] and psychological flexibility models [63], and those within 
the HIV literature that focus heavily on sociocultural perspectives to understand the impact 
of processes, such as stigma, on well-being [78].   
  The current findings suggest the relevance of psychosocial treatments to manage 
persistent pain in HIV. To our knowledge, only three small RCTs have evaluated cognitive-
behavioural therapy (CBT) and mindfulness-based treatment [29,35,118]. Non-randomized 
trials of CBT [113] and hypnosis [25] have also been conducted. Further evaluation of 
psychosocial treatments for HIV and chronic pain is thus needed. The development of 
treatments that specifically target psychosocial factors identified in this review with ‘some’ 
or ‘moderate’ evidence may prove fruitful. 
 Several limitations warrant consideration. We used a comprehensive search strategy 
that included efforts to identify grey literature to limit publication bias; however, relevant 
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studies may have been missed given the broad nature of the search. We used an adapted 
quality assessment tool. Although we based this on previously validated tools, the 
adaptations may have limited the reliability and validity of our quality assessment. 
Assessment of pain was inadequate in many studies. Future research should assess 
information regarding pain duration, intensity, location, and type. Studies investigating 
chronic pain should specify eligibility criteria in line with recognized definitions: the 
presence of daily, clinically meaningful pain intensity and functional interference for at least 
three months [10,26,131]. Given the relevance of neuropathic pain in this population, the 
use of well-validated screening tools of neuropathy signs and symptoms is important 
[16,33,129].  
This review identified a large number of psychosocial factors. As evidence on specific 
psychosocial factors develops in this area, it may be useful for a future review to use a more 
targeted approach to synthesize data on a smaller number of pre-specified variables. We 
focused on bivariate analyses and dichotomized multiple between-groups analyses to 
facilitate comparison across studies and minimise pairwise comparisons. However, this may 
have limited an in-depth understanding of psychosocial factors from multivariate models 
and more subtle subgroup analyses. Future research examining the association between 
psychosocial factors and pain outcomes in HIV should consider controlling for such variables 
as age, sex, race/ethnicity, socioeconomic status, HIV duration, current and nadir CD4+ 
count and current and peak viral load, current and past ART regimens, and other medical 
comorbidities (e.g., hepatitis C, diabetes, tuberculosis). Where multiple psychosocial 
variables are included, sufficient rationale for each variable should be provided and care 
should be taken to minimize overlap in assessment content between variables.   
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 Despite these limitations, this is the first systematic review to explore psychosocial 
variables associated with persistent pain in HIV. From this review it is recommended that 
researchers (a) focus greater attention on protective psychological factors and social 
processes, such as stigma and processes to undermine stigma; (b) use higher quality 
assessment tools; and (c) develop and test treatments to target key psychosocial factors to 
improve pain outcomes in HIV. Improving quality of life is a priority as people with HIV live 
longer. Adequate, whole-person pain management is vital to achieve this goal.  
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Figure Legend 
 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 
[75]) flow diagram. 
 
Figure 2. Forest plot of cross-sectional odds ratios (OR) for depression. Depression was more 
likely in participants with versus without pain, as reflected in the pooled odds ratio (OR) of 
>1. Note: CI, Confidence Interval. Grey boxes show weighting of individual studies; the red 
dotted line indicates the pooled effect around which effects from individual studies vary; 
the blue diamond shows the 95% CI around the pooled effect. 
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Figure 3. Forest plot of cross-sectional standardized mean differences (SMD) for depression. 
Depression symptoms were more severe in participants with versus without pain, as 
indicated by a positive pooled SMD. Note: CI, Confidence Interval; SD, standard deviation.  
  
Figure 4. Forest plot of cross-sectional events data for psychological distress. Distress was 
more likely in participants with versus without pain, as reflected in the pooled odds ratio 
(OR) of >1. Note: CI, Confidence Interval. 
 
Figure 5. Forest plot of cross-sectional standardized mean differences (SMD) for 
psychological distress. Distress was more severe in participants with versus without pain, as 
reflected by a positive pooled SMD. Note: CI, Confidence Interval; SD, standard deviation. 
 
Figure 6. Forest plot of cross-sectional events data for drug abuse. Drug abuse was more 
likely in participants with versus without pain, as reflected in the pooled odds ratio (OR) of 
>1. Note: CI, Confidence Interval. 
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Table 1. Summary of the evidence for psychosocial variables.  
Study Quality Psychosocial 
Assessment 
Study Design/Analyses Main Summary 
Depression    
High: (n=2) 
[79,84] 
Medium: (n=19)  
[2,27,29†,31,50,6
0,61,67,88,89,91,
92,96,97,102,104,
114,116,119] 
Low: (n=8) 
[8,28,39,55,57,95,
101,110] 
BDI*(n=11); BSI (n=2) 
CDC (n=1); CES-D (n=6) 
CIDI*(n=1); DAPOS (n=1) 
DASS (n=1); GAIN (n=1) 
HADS (n=1); HSC (n=1) 
PHQ (n=2); PRISM (n=1) 
Non-validated (n=1) 
 
-Prospective(HR) (n=2; Fig S1) 
-Prospective (OR) (n=2; Fig S2) 
-Cross-sectional (OR) (n=9, 
includes 1 cross-sectional case-
control; Fig 2) 
-Cross-sectional (SMD) 
 (n=13; Fig 3/text) 
-Cross-sectional (correlation) 
 (n=8; Fig S8/text ) 
Depression consistently 
positively associated with 
pain presence, intensity, and 
interference, and negatively 
with quality of life in 
prospective and cross-
sectional studies. 
 
Evidence level: Moderate 
Psychological Distress    
High: (n=1) [84] 
Medium: (n=11) 
[2,29†,31,44,47,5
0,61,66,86,88,91,
104] 
Low: (n=6) 
[5,53,54,57,65, 
110] 
BSI (n=2); CSQ (n=1) 
GAIN (n=1); HADS (n=1) 
HSC*(n=1); INTRP (n=1) 
PASS (n=1); PCS*(n=4) 
PHQ (n=1); POMS (n=1) 
PRISM (n=1) 
Clinician diagnosis1(n=1) 
Medical file (ICD-9, n=1; 
unclear, n=2) 
-Prospective (OR) (n=1; in text) 
-Prospective (correlation)  
(n=1; in text) 
-Cross-sectional (OR) (n=5; Fig 4) 
-Cross-sectional (SMD) 
(n=8; Fig 5/text ) 
-Cross-sectional (correlation) 
(n=5; Fig S9) 
Distress consistently 
positively associated with 
pain presence, intensity, and 
interference in cross-
sectional analyses, but this 
was not consistent in the two 
prospective studies.  
 
Evidence level: Some 
Post-traumatic Stress (PTSS)   
High: (n=1)[79] 
Medium: (n=2) 
[31,107] 
HTQ (n=1) 
PCL-C (n=1) 
PRISM (n=1) 
-Prospective (ANCOVA) (n=1; 
text) 
-Cross-sectional (SMD and   
 correlation) (n=1; text) 
-Cross-sectional (OR) (n=1; text) 
PTSS associated with poorer 
pain outcomes in one 
prospective and one high 
quality cross-sectional study. 
Evidence level: Some 
Drug Abuse    
Medium: (n=9) 
[47,52,60,67,76,9
2,104,114,119] 
Low: (n=5) 
[39,53,54,81,110] 
 
CIDI (n=1); DIS-IV (n=1) 
GAIN (n=1); PRISM (n=1) 
RBS (n=1) 
Medical file (ICD-9; n=1)  
Medical file (other; n=2) 
Other self-report (n=6) 
-Prospective (OR)(n=4; Fig 
S10/text) 
-Cross-sectional (OR) (n=8, 
includes 1 cross-sectional case-
control; Fig 6) 
-Cross-sectional (SMD) (n=1; text) 
-Cross-sectional (correlation) 
(n=1; text) 
Pain and drug abuse 
consistently positively 
associated in prospective 
and cross-sectional studies. 
 
Evidence level: Moderate 
Alcohol Abuse    
Medium: (n=8) 
[27,52,60,76,77, 
115,117,119] 
Low: (n=3) 
[6,39,56] 
CIDI (n=2); DIS-IV (n=1) 
DSM-IV (n=1); 
NIAAA(n=2) PRISM 
(n=1); SCID (n=1)  
Other self-report (n=2) 
Unclear (n=1) 
-Prospective (HR) (n=1; text) 
-Prospective (OR) (n=3; Fig 
S11/text) 
-Cross-sectional (OR) (n=7) (Fig 
S12) 
Lack of association between 
pain and alcohol abuse in 
cross-sectional studies; 
inconsistent findings in 
prospective studies. 
Evidence Level: 
Inconclusive 
Sleep Disturbance    
High: (n=1) [84] GSDS (n=1) -Cross-sectional (SMD) Sleep disturbance and pain 
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Medium: (n=2) 
[2,94] 
ISI (n=1) 
PSQI (n=1) 
(n=2; Fig S13) 
-Cross-sectional (correlation) 
(n=1; text)  
positively associated in 2/3 
cross-sectional studies. 
Evidence Level: Some 
ART Non-adherence   
Medium: (n=2) 
[66,68]  
Low: (n=5) 
[8,46,57,72,110] 
ACTG-AQ (n=5) 
Other self-report (n=2) 
-Prospective (OR) (n=1; text) 
-Cross-sectional (OR)  
(n=4; Fig S14/15) 
-Cross-sectional (correlation/SEM; 
n=2; text) 
Pain associated with reduced 
ART adherence in one 
prospective study and 
majority of cross-sectional 
studies. Evidence: Some 
Healthcare Use   
Medium: (n=4) 
[47,61,68,119] 
Low: (n=2) 
[39,53] 
Medical records 
(GP/HIV/urgent care 
visits) (n=4) 
Self-report (mental 
health treatment) (n=2) 
-Prospective (OR) (n=1; text) 
-Cross-sectional (OR) (n=2; Fig 
S16) 
-Cross-sectional (SMD) 
(n=3; Fig S17/text) 
Pain associated with greater 
healthcare use in one large 
prospective study and two 
large cross-sectional studies. 
No association in three 
relatively small cross-
sectional studies.  
Evidence level: Some 
Missed HIV Clinic Visits   
Medium: (n=2) 
[68,92] 
Medical records Prospective (OR) (n=2; Fig S18) Pain associated with greater 
missed HIV clinic visits based 
on pooled effect of two large 
prospective studies. 
Evidence level: Some 
Unemployment   
High: (n=1)[79] 
Medium: (n=7) 
[2,27,61,92,114,1
19,121] 
WPAIQ (n=1) 
Other self-report (n=7) 
 
Cross-sectional (OR) (n=8, 
includes 1 cross-sectional case-
control; Fig S19) 
Pain consistently associated 
with unemployment (cross-
sectional studies). 
Evidence level: Some 
Protective Factors   
High: (n=1) [79] 
Medium: (n=2) 
[86,121] 
Low: (n=2) 
[8,101] 
-ACTG-AQ self-efficacy 
item (n=1) 
-CPAQ (n=1) 
-Life Orientation Test 
(n=1) 
-The Resilience Scale 
(n=1) 
-SE-6 (n=1) 
 
-Prospective (correlation) (n=1) 
-Cross-sectional (OR) (n=1) 
-Cross-sectional 
(SMD/correlation) (n=3, includes 
1 cross-sectional case-control) 
-All discussed in text 
Resilience (1 case-control), 
acceptance (1 prospective), 
and self-efficacy (2 cross-
sectional, incl. 1 high quality) 
associated with improved 
pain outcomes. Optimism 
examined in only one low 
quality cross-sectional study 
Evidence level: Some 
Social Factors   
Medium: (n=3) 
[73,74,91,122] 
Low: 
(n=2)[72,98] 
-HASI-P (n=1) (stigma) 
-RSS (n=1) (stigma) 
-SSQ-SF (n=1) (support 
quality/number) 
-Self-report: negative 
support/support 
reciprocity/patient- 
provider engagement 
(not validated; n=1) 
Prospective (correlation) (n=1) 
Cross-sectional (OR) (n=1) 
Cross-sectional (SMD/correlation) 
(n=3) 
-All discussed in text 
 
-Too few studies, lack of high 
quality studies, and some 
inconsistencies for social 
processes (e.g., negative 
support/support quality) 
Evidence level: 
Inconclusive 
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D
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Note: As justified in the Methods, we chose to focus on interpreting bivariate data. 
However, studies reporting a multivariate model between psychosocial and pain 
variables are bolded in column 1 for ease of reference. †Reference for multivariate 
analyses related to bivariate data reported in [29] is [38]. 
ACTG-AQ, AIDS Clinical Trials Group Adherence Questionnaire; BDI, Beck Depression 
Inventory; BSI, Brief Symptom Inventory; CES-D, Centre for Epidemiological Studies 
Depression Scale; CIDI, Composite International Diagnostic Interview; CPAQ, Chronic 
Pain Acceptance Questionnaire; CSQ, Coping Strategies Questionnaire; DAPOS, 
Depression, Anxiety, and Positive Outlook Scale; DASS, Depression Anxiety Stress 
Scales; DIS-IV, Diagnostic Interview Schedule for DSM-IV (Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition); GAIN, Global Appraisal of Individual Needs; 
GSDS; General Sleep Disturbance Scale; HADS, Hospital Anxiety and Depression Scale; 
HASI-P, HIV/AIDS Stigma Scale—People Living with AIDS; HSC, Hopkins Symptoms 
Checklist; HTQ, Harvard Trauma Questionnaire; ICD-9, International Classification of 
Disease mental illness/substance abuse codes extracted from medical file; INTRP, 
Inventory of Negative Thoughts in Response to Pain; ISI, Insomnia Severity Index; 
NIAAA, National Institute on Alcoholism and Alcohol Abuse Guidelines; PASS, Pain 
Anxiety Symptom Scale; PCL-C: PTSD Checklist-Civilian; PCS, Pain Catastrophizing Scale; 
PHQ, Patient Health Questionnaire Depression/Anxiety Module; POMS, Profile of Mood 
States—Tension/Anxiety; PRISM, Psychiatric Research Interview for Substance and 
Mental Disorders; PSQI, Pittsburgh Sleep Quality Index; RBS, Risk Behaviour Survey; 
RSS, Reece Stigma Scale; SCID, Structured Clinical Interview for DSM-IV; SE-6, Self-
Efficacy for Managing Chronic Disease—6 Item Scale; SSQ-SF, Social Support 
Questionnaire—Short Form; WPAIQ, Work Productivity and Activity Impairment 
Questionnaire; 
1
Patient report of diagnosis of mental illness by a clinician.  
*Where different measures of the same variable were used for between-group and 
within group analyses in the same study, both measures are reported. 
HR, Hazard Ratio; OR, Odds Ratio; SEM, Structural Equation Model; SMD, Standardized 
Mean Difference. 
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Records identified through 
database searching 
(n=4458) 
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Additional records identified 
through other sources 
(n=8) 
Records after duplicates removed 
(n=3733) 
Records screened 
(n=3733) 
Records excluded 
(n=3367) 
Full-text articles assessed 
for eligibility 
(n=366) 
Full-text articles excluded,  
with reasons (n=299) 
 
-Participants <18 years old (n=2) 
 
-Not HIV or cannot extract HIV 
subsample (n=17) 
 
-Not chronic pain, or cannot 
extract measure of 
pain/psychosocial association for 
(sub-)sample with pain (n=221) 
 
 
-No modifiable psychosocial 
factors (n=36) 
 
-Duplicate (n=14) 
 
-Review or letter (n=7) 
 
-Qualitative (n=2) 
 
Studies included in 
qualitative synthesis 
(n =46 studies across 67 
papers; 63 published, 3 
dissertations, 1 
unpublished full-text) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n=37) 
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 83.0%, p = 0.000)
Ellis et al. (2010)
Simms et al. (1992)
Merlin et al. (2017)
Fellows et al (2012)
Safo et al. (2017)
Robbins et al. (2013)
Hansen et al. (2011)
Study
Berg et al. (2009)
Tsui et al. (2013)
881
58
140
278
851
254
270
N
70
699
2.65 (1.62, 4.34)
1.61 (1.12, 2.33)
9.72 (0.54, 176.63)
125.96 (7.50, 2114.01)
0.89 (0.53, 1.49)
4.72 (3.37, 6.59)
2.70 (1.40, 5.00)
8.79 (2.01, 38.40)
OR (95% CI)
2.17 (1.01, 4.69)
2.02 (1.49, 2.74)
100.00
15.81
2.46
2.58
%
14.52
16.03
13.42
6.76
Weight
12.17
16.24
No Pain Group  Pain Group 
1.1 .5 510
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 89.2%, p = 0.000)
Saylor et al. (2017)
Parker et al. (2017)
Evans et al. (1998)
Rosenfeld et al. (1996)
Simmonds et al. (2005)
Phillips et al. (2014)
Uebelacker et al. (2015)
Study
Singer et al. (1996)
Kirkland (2012)
Surratt et al. (2015)
Aouizerat et al. (2010)
Mann et al. (2015)
0.68 (0.42, 0.93)
0.29 (0.04, 0.54)
0.59 (0.29, 0.89)
0.73 (0.37, 1.10)
0.53 (0.34, 0.73)
0.40 (-0.00, 0.81)
0.68 (0.09, 1.28)
0.94 (0.66, 1.22)
SMD (95% CI)
0.38 (0.06, 0.70)
2.26 (1.90, 2.62)
0.72 (0.54, 0.90)
0.47 (0.25, 0.70)
0.16 (-0.30, 0.62)
1419
76, 12.3 (10)
170, 18.5 (10.4)
40, 13.3 (8.1)
274, 19.6 (10.5)
50, 19.5 (10.9)
19, 11.2 (4.22)
107, 14.8 (8.09)
(SD); Pain
69, 1 (.9)
N, mean
103, 27.2 (12.9)
258, 6.34 (2.64)
175, 19 (10.7)
78, 8.63 (3.8)
1442
323, 9.6 (9.1)
59, 12.6 (9)
121, 7.7 (7.5)
164, 14.3 (9.2)
46, 15.2 (10.3)
29, 8.38 (4.1)
107, 8.14 (5.96)
(SD); No Pain
89, .7 (.7)
N, mean
93, 4.03 (6.12)
245, 4.3 (3)
142, 14.2 (9.5)
24, 8 (4.3)
100.00
8.90
8.57
8.10
9.20
7.82
6.36
8.69
Weight
8.46
%
8.16
9.28
9.05
7.41
No Pain Group  Pain Group 
0-1 -.5 .5 1 1.5
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 68.3%, p = 0.013)
Merlin, Cen, et al. (2012)
Fellows et al. (2012)
Merlin et al. (2015)
Koeppe et al. (2010)
Jiao et al. (2016)
Study
2.56 (1.67, 3.90)
4.11 (2.00, 8.44)
0.74 (0.28, 1.99)
6.88 (2.38, 19.94)
2.13 (1.64, 2.77)
2.69 (1.94, 3.73)
OR (95% CI)
393/832
37/76
8/150
13/30
176/324
Events,
159/252
Pain
466/1460
15/80
9/128
7/70
285/796
Events,
150/386
No Pain
100.00
17.38
12.11
10.90
30.76
%
28.85
Weight
No Pain Group  Pain Group 
1.25 .5 2.5 5
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 95.4%, p = 0.000)
Mann et al. (2015)
Surratt et al. (2015)
Study
Singer et al. (1996)
Phillips et al. (2014)
Kirkland (2012)
Aouizerat et al. (2010)
Rosenfeld et al. (1996)
0.85 (0.35, 1.35)
-0.23 (-0.69, 0.22)
0.74 (0.56, 0.92)
SMD (95% CI)
0.77 (0.45, 1.10)
0.79 (0.20, 1.39)
2.78 (2.38, 3.17)
0.36 (0.14, 0.58)
0.74 (0.54, 0.94)
976
78, 10.1 (3.36)
258, 5.84 (3.54)
(SD); Pain
N, mean
69, 1 (.8)
19, 23.7 (12.6)
103, 34.9 (14.6)
175, 9.8 (7.4)
274, 1.26 (.7)
788
24, 10.9 (4.1)
245, 3.3 (3.3)
(SD); No Pain
N, mean
89, .5 (.5)
31, 14.1 (11.8)
93, 3.09 (6.32)
142, 7.3 (6.4)
164, .79 (.5)
100.00
13.65
15.12
Weight
%
14.47
12.67
14.07
14.96
15.05
No Pain Group  Pain Group 
0-1 -.5 .5 1 1.5 2
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 69.8%, p = 0.002)
Koeppe et al. (2010)
Safo et al. (2017)
Jiao et al.  (2016)
Morgello et al. (2004)
Singer et al. (1996)
Study
Uebelacker et al. (2015)
Hansen et al.  (2011)
Merlin et al. (2017)
1.59 (1.12, 2.26)
1.36 (1.04, 1.78)
1.57 (1.02, 2.42)
2.23 (1.59, 3.14)
0.22 (0.08, 0.63)
2.49 (1.43, 4.33)
OR (95% CI)
1.38 (0.55, 3.41)
1.82 (0.59, 5.62)
2.67 (1.30, 5.45)
485/1357
123/324
Events,
36/208
108/252
26/65
69/98
Pain
12/107
75/240
36/63
537/2176
247/796
Events,
76/646
97/386
18/24
64/131
No Pain
9/107
4/20
22/66
100.00
18.66
%
15.95
17.55
7.34
13.83
Weight
8.76
6.66
11.26
No Pain Group  Pain Group 
1.1 .5 2 5
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